Disease · HP_0030839
Knee pain
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Knee pain. Diseases, record HP_0030839. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0030839
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Knee pain
- Open Targets ID
- HP_0030839
- Highest stage of its drugs
- Phase 3, for 6 of its 23 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs23
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DULOXETINE | CHEMBL1175 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DICLOFENAC | CHEMBL139 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LETIBOTULINUMTOXINA | CHEMBL3707322 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| ONABOTULINUMTOXINA | CHEMBL1201574 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| RESVERATROL | CHEMBL165 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYALURONIC ACID | CHEMBL5314376 | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets | |
| AMITRIPTYLINE | CHEMBL629 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BACLOFEN | CHEMBL701 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETOPROFEN | CHEMBL571 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 23
See all 23 drugsTargets21
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS2 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 2/3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 3 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Phase 2/3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Phase 2/3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Phase 2/3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Phase 2/3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Phase 2/3 | https://conductscience.org/library/genes/6328 | Drugs and targets |
1 to 10 of 21
See all 21 targetsTrials24
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01018680 | A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis | Phase 3 | 524 | 2012-10-05 | Osteoarthritis Knee Pain | DULOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT02248480 | A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan | Phase 3 | 354 | 2017-01-16 | Osteoarthritis of the Knee | DULOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT02335346 | An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480) | Phase 3 | 93 | 2017-11-07 | Osteoarthritis of the Knee | DULOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT02701296 | Posterior Capsular Injection With Femoral Nerve Block for Total Knee Arthroplasty | Not applicable | 80 | 2017-06-14 | Posterior Knee Infiltration | ROPIVACAINE | Its record names the disease | ClinicalTrials.gov |
| NCT05450458 | Hyaluronic Acid in Overuse Knee Pain | Phase 2/3 | 64 | 2025-07-22 | Overuse Injury, Body Mass Index in Athletes | HYALURONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT02184156 | A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain | Phase 1/2 | 47 | 2022-09-30 | Osteoarthritis of the Knee | ASPARTYL-ALANYL-DIKETOPIPERAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT02930122 | IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions | Phase 2 | 6 | 2021-10-27 | Anterior Cruciate Ligament Tear | ANAKINRA, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00496964 | Botox for Non-surgical Lateral Release in Patellofemoral Pain | Phase 3 | 5 | 2011-05-18 | Patellofemoral Pain Syndrome | BOTULINUM TOXIN TYPE A, ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT06257537 | Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis | Phase 2 | 307 | Osteo Arthritis Knee, Arthritis | DICLOFENAC | Its record names the disease | ClinicalTrials.gov | |
| NCT02905799 | Resveratrol in Knee Osteoarthritis | Phase 3 | 142 | Knee Osteoarthritis | RESVERATROL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Duloxetine vs Placebo: serious adverse events | 5 of 264 | 3 of 260 | 524 | NCT01018680 | Trial comparisons |
| Duloxetine vs Placebo: serious adverse events | 1 of 178 | 1 of 176 | 354 | NCT02248480 | Trial comparisons |
| Posterior Capsular Injection vs Tibial Nerve Block: deaths from any cause | 0 of 42 | 0 of 36 | 78 | NCT02701296 | Trial comparisons |
| Posterior Capsular Injection vs Tibial Nerve Block: serious adverse events | 0 of 42 | 0 of 36 | 78 | NCT02701296 | Trial comparisons |
| Arm 1 vs Placebo Control: deaths from any cause | 0 of 3 | 0 of 3 | 6 | NCT02930122 | Trial comparisons |
| Arm 1 vs Placebo Control: serious adverse events | 0 of 3 | 0 of 3 | 6 | NCT02930122 | Trial comparisons |
| Botulinum Toxin A Injection + Exercise vs Placebo Injection + Exercise: serious adverse events | 0 of 1 | 0 of 4 | 5 | NCT00496964 | Trial comparisons |
Papers from its trials73
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0030839
GET https://conductscience.org/api/diseases/v1/HP_0030839/drugs?page=2